Evgen Pharma Share Discussion Threads

[teddy boy1] 04/6/2018 14:25

If "we get a sniff" that things are going well in the update coming shortly (interim) the share price could go into orbit is there was only a small free float.

Judging by the brokers target price they too see a lot of potential here.

The company has made it easy for anyone wanting to research Evgen Pharma as all the tests ,trails and results are very well documented.

This is definitely one to watch but do not leave it too long as time is running out for anyone who wants a piece of the action. DYOR

[teddy boy1] 04/6/2018 11:06

Nice to see the share price trending upwards! A steady stream of BUYs this morning.I have a strong suspicion that there are quite a few "watchers" here who are poised ready to press the BUY button.

[teddy boy1] 04/6/2018 10:36

NICO115 I will drink to to that !. According to my sources this share is continuing to cause "excitement" in the City . However, DOYR.

[nico115] 04/6/2018 07:51

This is my share of the week as we run up to the read out Expecting very positive data

[nobbygnome] 03/6/2018 13:47

There is no doubt 20% is the key number. This is from the KOLs in the field and not EVG.

Nobby

[pdt] 03/6/2018 11:52

There is a new article in Shares magazine. Here is the PDF link from Evgen's website;



I don't think there is anything new except that Franklin mentions that their clinical advisors point to the target of 20% or more patients having their tumour growth halted for six months as a good indication of an interesting drug.

At the time of being interviewed for the article he must have a pretty good idea of the results to be announced and may be setting expectations. I think we should be celebrating with anything showing 25% plus as investors. If I was a patient who had run out of treatment options and was offered a safe, well tolerated, drug with a 1 in 4 chance of extending my life by at least 6 months I would grab it!

The release of interim data is again confirmed as June. It is an upbeat article :)

[bernymadoff] 03/6/2018 09:24

Not long to wait now for the interim readouts.

This is from the 8 Dec rns:

"STEM ('SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer') is a multi-centre, Phase IIa clinical trial. Led by Chief Investigator Dr Sacha Howell of the Christie Hospital in Manchester, the trial is recruiting 60 patients from multiple sites in the UK, Belgium, France and Spain - seven sites in total are currently open for recruitment across these countries and 18 patients have been enrolled to date. We are projecting the read-out from the study in the second half of calendar year 2018. As the study is open label, the Company will issue an interim data analysis in the first half of calendar year 2018.

�

All STEM patients will have ER+ metastatic breast cancer and will have been on treatment with either tamoxifen, aromatase inhibitors (AI) or fulvestrant. Prior to entry to the STEM trial, patients must have previously responded to their current hormone therapy for at least six months but then present with progressive disease, thereby demonstrating the start of resistance to the hormone therapy. Once entered into the trial, patients continue to receive their hormone therapy in addition to SFX-01 and have regular scans through to week 24. Patients discontinue the trial when one of the scans shows disease progression or at week 24."

Assuming they had commenced dosing this cohort by mid Dec it would mean that the 24-week trial is finished now.

I would expect the company has all the data and is analysing it right now.

Exciting times

[peterm10] 01/6/2018 01:11

Am still chomping the sprouts until I can get the seed or the magic tablet . Gotta play the percentages

[nobbygnome] 31/5/2018 10:54

I think the point is that you get little benefit from eating the vegetable itself. The secret is in the formulation of the compound which is very unstable. So sadly there isn't much point in stuffing yourself full of broccoli as it isn't going to stop you getting cancer etc. I am sure it contains vitamins and of course roughage so as with all vegetables it is overall good for you but not specifically in relation to what Evgen is evaluating.

Nobby

[peterm10] 31/5/2018 10:49

Diet tips and share tips on the same board. Win win

[frost1] 31/5/2018 09:03

Vegus juices in Ireland and tonic attack England for concentrated broccoli drinks. I find them v good. Watching this share. Hoping to invest soon.

[melodrama] 31/5/2018 05:06

pete I sprout all kinds of stuff but the Broccoli seeds are hugely full of the good stuff, heat them to 70 C for 10 mins before you heat them as max the Sulf stuff



Have to say it's s bit of a pfaff sprouting and ditto me paying a quid

[peterm10] 30/5/2018 23:07

Very exciting times and the funeral of a relative from cancer today made me look again at the natural occurring versions for prevention . According to most articles broccoli sprouts (sprouting seeds) are 10 to 100 x more potent than other veg such as broccoli itself. Bought a couple of punnets today and will try and grow it .. seems easy. Tastes ok but don't cook it. Anyway where I am rambling to is I would pay a quid a day for a non prescription tablet with the magic ingredients. Size of that market is huge

[teddy boy1] 30/5/2018 22:01

Roll on the 13th June .It could be a really good day for all concerned !

make sure that you get your share of the action !

[melodrama] 30/5/2018 12:06

If there's any chance of bad news why would they go to the trouble of inviting analysts. Ergo, must be good news.

[pdt] 30/5/2018 11:48

Stroke is an area of interest for Evgen with the SAH trial on-going and pre-clinical work being conducted by Kings. Therefore it is of interest that a new research paper has been published of the work by Imperial and others in respect of Stroke;

"The Isothiocyanate Sulforaphane Modulates Platelet Function and Protects Against Cerebral Thrombotic Dysfunction"

The conclusion reads; Data presented here provides evidence for the use of SFN in preventing stroke in selected high‐risk patient cohorts



And today I see the final results are out on 13th June followed by an Analyst meeting. I suspect that would be a good day to release the interim trial results as well.

[bernymadoff] 30/5/2018 01:18

It will likely rise into interims and if they are positive the tight free float will exaggerate any rise. My personal calcs show that the 24 week trial will end any time from the end of the first week of June. Results could land at any time after that.

[nobbygnome] 29/5/2018 22:56

Couldn’t agree more. Of course we don’t know precisely when the results will be announced but is likely to be towards the end of June. If so, the chances are the price will be much higher then than it is now. After all the current market cap is only £20 million.....

Nobby

[teddy boy1] 29/5/2018 22:51

This share is definitely one to hold ! From my perspective ,it is very tightly held and thus when we get a sniff of good news on the ongoing phase 2 trials, it will cause the price to rocket.Don,t miss out on your share of the action!

[nico115] 29/5/2018 18:34

SharesocSorry NOONE caresMany Aim directors can't be trusted You should look into helping shareholders like me hold them to account Not evg but others

[sharesoc] 29/5/2018 16:44

Evgen Pharma present at our Manchester growth company seminar on the 19th June. This may be of interest to potential investors and current shareholders, there are limited places at this event!

[teddy boy1] 29/5/2018 15:51

If you take out the 50,000 cancelled buy on FRIDAY shown in todays trades then the buys easily outweigh the sells.

Perhaps the message is getting through about what a good prospect Engen Pharma actually is !

[teddy boy1] 29/5/2018 14:41

Just done some more in-depth research on this share (should have done it before I bought ,but wanted to get in quick!) and I get more excited about the prospects by the minute.


One of the most exciting opportunities that I have come across for some time!

[teddy boy1] 29/5/2018 12:27

Both IMM and Evgen are pharmas at similar stages of their developments. Hence I cannot see any harm in comparing the two. Perhaps we could even learn something!